Emergent Biosolutions (NYSE:EBS) Director Kathryn C. Zoon Sells 7,086 Shares

Key Points

• Emergent Biosolutions Inc. Director Kathryn C. Zoon sold 7,086 shares of stock for a total of $62,852.82, decreasing her position by 8.98% and leaving her with 71,799 shares.
• The company's stock increased by 2.5% recently, trading at $9.06 with a market cap of $483.36 million.
• Wall Street Zen downgraded Emergent Biosolutions from a "buy" to a "hold" rating on August 9th, indicating a shift in analyst sentiment towards the stock.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Kathryn C. Zoon sold 7,086 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares of the company's stock, valued at $636,857.13. The trade was a 8.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Emergent Biosolutions Price Performance

NYSE EBS traded down $0.0850 during trading hours on Friday, reaching $9.2350. The company's stock had a trading volume of 1,236,019 shares, compared to its average volume of 1,481,953. The firm has a market capitalization of $492.69 million, a price-to-earnings ratio of 3.77 and a beta of 1.97. Emergent Biosolutions Inc. has a 1-year low of $4.02 and a 1-year high of $12.73. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. The company's 50-day moving average is $7.22 and its two-hundred day moving average is $6.51.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.42. The company had revenue of $140.90 million during the quarter, compared to analysts' expectations of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. On average, equities analysts predict that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $14.33.

Institutional Investors Weigh In On Emergent Biosolutions

Several large investors have recently bought and sold shares of EBS. LPL Financial LLC grew its position in shares of Emergent Biosolutions by 34.5% in the fourth quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 3,875 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Emergent Biosolutions by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 590,862 shares of the biopharmaceutical company's stock valued at $5,651,000 after purchasing an additional 8,904 shares in the last quarter. Envestnet Asset Management Inc. purchased a new stake in shares of Emergent Biosolutions in the fourth quarter valued at approximately $331,000. Invesco Ltd. grew its position in shares of Emergent Biosolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after purchasing an additional 638,995 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Emergent Biosolutions by 26.8% in the fourth quarter. Renaissance Technologies LLC now owns 665,847 shares of the biopharmaceutical company's stock valued at $6,365,000 after purchasing an additional 140,900 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.